The product is bioequivalent and therapeutically equivalent to Fresenius Kabi’s reference drug (NDA 212832)
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
The trial’s primary goal is to evaluate vipoglanstat’s effect on endometriosis-related pain during non-menstrual days
The expansion builds on Veristat’s work helping Chinese pharmaceutical firms such as Hansoh Pharma and CStone Pharmaceuticals
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The approval comes after a systematic review of published literature
The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
Diasens and GlucoLive are designed for diabetic, Chronic Kidney Disease (CKD), and post-transplant patients who require continuous glycaemic surveillance and integrated remote care
The Hydrus Microstent stands out as the first and only MIGS device backed by five-year clinical outcomes
Subscribe To Our Newsletter & Stay Updated
